Ekso Bionics Holdings Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Ekso Bionics Holdings Inc (EKSO) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Ekso Bionics Holdings Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 96M vs -M combined for tracked competitors (100.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+73.3% annualized vs trailing 12 months).
- Peer revenue share: Ekso Bionics Holdings Inc accounted for 100.0% of combined revenue among its tracked peer group, up from 100.0% a year earlier.
- Peer differentiation: Revenue per employee of $3.09M compares with $0.13M for the peer group (23.5x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
EKSO Sales vs. its Competitors, Q1 2026
Ekso Bionics Holdings Inc generated 100.00 % of the combined sales of its peer group, up from 100.00 % a year earlier.
For context: the Industrial Machinery and Components industry grew revenue 13.9% year over year, combined, vs 1,068.8% for Ekso Bionics Holdings Inc. Ekso Bionics Holdings Inc's share of combined industry revenue moved from 0.00% to 0.03%, a gain of 0.03 percentage points.
Ekso Bionics Holdings Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Ekso Bionics Holdings Inc | No | Yes | Yes | Yes |
| Competitors combined (2) | ||||
| High-Confidence Competitors (6) | ||||
| Similar Growth & Profitability (8) | 42.90 % (3 of 7) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
EKSO Stock Performance relative to its Competitors
EKSO Stock Performance relative to High-Confidence Competitors
EKSO Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Lifeward ltd | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Ekso Bionics Holdings Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Ekso Bionics Holdings Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Ekso Bionics Holdings Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Ekso Bionics Holdings Inc | 1,715.81 | 95.75 |
| Lifeward ltd | 16.78 | 21.82 |
| Ss Innovations International Inc | - | 52.20 |
| SUBTOTAL | 1,732.59 | 169.77 |
Sources: Ekso Bionics Holdings Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Ekso Bionics Holdings Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Ekso Bionics Holdings Inc's Competitors Named by the Company
Competitive relationships identified from Ekso Bionics Holdings Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Lifeward ltd | Company report | 85% |
| Nebius Group | Company report | 85% |
| Crusoe Energy | Company report | 85% |
| Lambda Labs | Company report | 85% |
| CoreWeave | Company report | 85% |
| Myomo Inc | Company report | 85% |
| Ottobock | Company report | 85% |
| Skel-ex | Company report | 85% |
| Bionik Laboratories | Company report | 85% |
| SuitX | Company report | 85% |
| Levitate | Company report | 85% |
| Reha Technology | Company report | 85% |
| Aretech | Company report | 85% |
| Hocoma | Company report | 85% |
| ReWalk | Company report | 85% |
| Parker Hannafin | Company report | 85% |
| AlterG | Company report | 85% |
| ReWalk Robotics | Company report | 85% |
| Cyberdyne | Company report | 85% |
Company report basis, confidence, active dates and source counts for Ekso Bionics Holdings Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Ekso Bionics Holdings Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Ekso Bionics Holdings Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Ekso Bionics Holdings Inc | 1,716 | 3,088,548 | -2,735,935 |
| Lifeward ltd | 17 | 269,407 | -380,617 |
| Ss Innovations International Inc | - | 108,071 | -24,835 |
| PEERS TOTAL | 17 | 131,242 | -75,931 |
Ekso Bionics Holdings Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Lifeward ltd | US 61.35 % |
| Ss Innovations International Inc | IN 98.66 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Ekso Bionics Holdings Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 129 companies in Ekso Bionics Holdings Inc's industry classification, broader than the peer set above. Market cap in millions of $.Ekso Bionics Holdings Inc ranks #0 of 129 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,667, indicating a moderately concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Asml Holding Nv | 638,387 | 33.93 % |
| 2 | Lam Research Corporation | 332,855 | 17.69 % |
| 3 | Deere and Co | 173,751 | 9.23 % |
| 4 | Eaton Corporation Plc | 152,392 | 8.10 % |
| 5 | Illinois Tool Works Inc | 1,234 | 5.2% |
| 6 | Bloom Energy Corporation | 1,234 | 5.2% |
| 7 | Carrier Global Corporation | 1,234 | 5.2% |
| 8 | Ingersoll Rand Inc | 1,234 | 5.2% |
| 9 | Dover Corp | 1,234 | 5.2% |
| 10 | Nvent Electric Plc | 1,234 | 5.2% |
| 0 | Ekso Bionics Holdings Inc | 42 | 0.00 % |
Market cap and industry share for the rest of Ekso Bionics Holdings Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-05-15.
Ekso Bionics Holdings Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Industrial Machinery and Components industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (180 companies). See the full Industrial Machinery and Components industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | -1.46 % | 26.84 % (avg) | -28.3 pp |
| Operating Margin | -60.01 % | industry median | -54.3 pp |
| EBITDA Margin | 40.30 % | 2.19 % (avg) | +38.1 pp |
| Capital Intensity (Capex / Revenue) | - | 6.64 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Ekso Bionics Holdings Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 54.11 % | 22.81 % | -36.18 % | 26.62 % | 14.81 % | 40.02 % | -3.14 % | -32.36 % |
| Operating Margin | -238.53 % | -119.56 % | -149.64 % | -122.96 % | -120.48 % | -83.59 % | -59.73 % | - |
| Return on Invested Capital | -133.74 % | -101.45 % | -88.50 % | -16.44 % | -24.09 % | -36.42 % | -30.38 % | -51.84 % |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Ekso Bionics Holdings Inc's Strategic Group Map
Every company in Ekso Bionics Holdings Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Ekso Bionics Holdings Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Ekso Bionics Holdings Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,667 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Ekso Bionics Holdings Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Ekso Bionics Holdings Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Ekso Bionics Holdings Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Ekso Bionics Holdings Inc falls in the Medium attractiveness / High strength cell: Invest / Grow.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Ekso Bionics Holdings Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+73.3% annualized vs trailing 12 months).
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Operating margin 54.3 points below the industry median.
- Return on equity 66.6 points below the industry aggregate.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
No rule matched.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Ekso Bionics Holdings Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Ekso Bionics Holdings Inc | 0.15 | 0.50 | 0.05 |
| Lifeward ltd | 0.68 | 1.97 | 0.41 |
| Ss Innovations International Inc | 0.37 | 2.23 | 0.26 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Ekso Bionics Holdings Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Ekso Bionics Holdings Inc | Q3 2026 | +1,068.8 % | - |
| Lifeward ltd | Q2 2026 | +15.7 % | - |
| Ss Innovations International Inc | Q2 2026 | +39.4 % | - |
| PEERS TOTAL | +221.9 % | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Ekso Bionics Holdings Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Ekso Bionics Holdings Inc | Q3 2026 | +4,462.8 % | +25,425.0 % |
| Lifeward ltd | Q2 2026 | +21.8 % | - |
| Ss Innovations International Inc | Q2 2026 | +67.4 % | +335,047.9 % |
Ekso Bionics Holdings Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Ekso Bionics Holdings Inc | - | - | - |
| Lifeward ltd | - | - | - |
| Ss Innovations International Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Ekso Bionics Holdings Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Ekso Bionics Holdings Inc | - | 17.92 |
| Lifeward ltd | - | 0.77 |
| Ss Innovations International Inc | - | - |
| PEERS AVERAGE | - | 10.21 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.